| 000 | 01860 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250514214544.0 | ||
| 264 | 0 | _c20050503 | |
| 008 | 200505s 0 0 eng d | ||
| 022 | _a0143-3334 | ||
| 024 | 7 |
_a10.1093/carcin/bgi025 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRashmi, Ramachandran | |
| 245 | 0 | 0 |
_aHuman colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL. _h[electronic resource] |
| 260 |
_bCarcinogenesis _cApr 2005 |
||
| 300 |
_a713-23 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aApoptosis Inducing Factor |
| 650 | 0 | 4 | _aCaspase Inhibitors |
| 650 | 0 | 4 |
_aCaspases _xmetabolism |
| 650 | 0 | 4 |
_aColonic Neoplasms _xmetabolism |
| 650 | 0 | 4 | _aComplement Membrane Attack Complex |
| 650 | 0 | 4 | _aComplement System Proteins |
| 650 | 0 | 4 |
_aCurcumin _xpharmacology |
| 650 | 0 | 4 |
_aCytochromes c _xmetabolism |
| 650 | 0 | 4 | _aDown-Regulation |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEnzyme Activation _xdrug effects |
| 650 | 0 | 4 |
_aFlavoproteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aGlycoproteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMembrane Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aOligonucleotides, Antisense _xpharmacology |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xgenetics |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 | _abcl-2-Associated X Protein |
| 650 | 0 | 4 | _abcl-X Protein |
| 700 | 1 | _aKumar, Santhosh | |
| 700 | 1 | _aKarunagaran, Devarajan | |
| 773 | 0 |
_tCarcinogenesis _gvol. 26 _gno. 4 _gp. 713-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/carcin/bgi025 _zAvailable from publisher's website |
| 999 |
_c15340694 _d15340694 |
||